Apoglyx is a pre-clinical stage virtual biotech company with the aim to develop an oral therapy for type 2 diabetes patients.
Apoglyx has raised $697K in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2021.
Apoglyx's investors include Almi Invest, LU Innovation.
Apoglyx is headquartered in Lund, Sweden.
Apoglyx is a pre-clinical stage virtual biotech company with the aim to develop an oral therapy for type 2 diabetes patients.
Apoglyx is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Apoglyx — Funding & Investors." VCBacked, October 25, 2021, https://www.vcbacked.co/company/apoglyx. Accessed August 14, 2026.
VCBacked. (2021). Apoglyx — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/apoglyx
{{cite web |title=Apoglyx — Funding & Investors |url=https://www.vcbacked.co/company/apoglyx |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated